NCT03419286 Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment Status COMPLETED Phase N/A
NCT03410368 NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer. Status UNKNOWN Phase PHASE2
NCT03406715 Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) Status TERMINATED Phase PHASE2
NCT03392064 A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC Status SUSPENDED Phase PHASE1
NCT03391362 Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases Status ACTIVE_NOT_RECRUITING Phase NA
NCT03389087 Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer Status UNKNOWN Phase PHASE2
NCT03366675 AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] Status TERMINATED Phase PHASE2
NCT03365791 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Status COMPLETED Phase PHASE2
NCT03345485 Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. Status COMPLETED Phase PHASE1/PHASE2
NCT03334487 Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer Status WITHDRAWN Phase PHASE3
NCT03325816 Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT03228667 QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03219762 Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC Status UNKNOWN Phase PHASE2
NCT03216343 Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer Status COMPLETED Phase PHASE1
NCT03116971 Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) Status TERMINATED Phase PHASE1
NCT03106155 Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification Status TERMINATED Phase PHASE2
NCT03098030 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Status COMPLETED Phase PHASE2/PHASE3
NCT03093688 Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor Status RECRUITING Phase PHASE1/PHASE2